Travere Therapeutics Inc
Travere Therapeutics Inc is a biopharmaceutical company that focuses on the development and commercialization of therapies for rare and orphan diseases.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Travere Therapeutics stock, expecting its value to rise from $23.01 to $20.57.
Financial Health
Travere Therapeutics is performing well with strong revenue and cash flow, indicating good financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring TVTX
Orphan Drug Moats: Leaders In Rare Disease
The FDA's rejection of PTC Therapeutics' drug for a rare genetic disorder has delayed a new treatment option and created a significant setback for the company. This regulatory decision strengthens the competitive position of companies with already-approved therapies for rare diseases, highlighting the value of a proven drug portfolio.
Published: August 20, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline Catalysts Ahead
Clinical readouts and regulatory milestones can move the stock; these events offer potential upside but also carry clear binary risk.
Specialist Market Focus
Concentrating on rare kidney diseases may allow premium pricing and focused uptake in specialist centres, though patient‑population size limits scale.
Commercial & Reimbursement
Successful commercialisation depends on payer decisions and clinic adoption; reimbursement dynamics can materially affect revenue prospects.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals develops treatments for diseases including cystic fibrosis and cancer.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals is a leading biotechnology company that develops and manufactures innovative medicines for serious medical conditions.
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics based on RNA interference (RNAi).
